Biotest AG
Biotest AG (BTTAY) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Biotest AG (BTTAY), covering cash flow, earnings, and balance sheets.
Biotest AG (BTTAY) Income Statement & Financial Overview
Explore comprehensive income reports for Biotest AG BTTAY, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $124.20M | $203.50M | $150.70M | $156.80M |
| Cost of Revenue | $110.10M | $150.60M | $121.50M | $105.70M |
| Gross Profit | $14.10M | $52.90M | $29.20M | $51.10M |
| Gross Profit Ratio | $0.11 | $0.26 | $0.19 | $0.33 |
| R&D Expenses | $15.10M | $10.60M | $17.00M | $14.20M |
| SG&A Expenses | $20.60M | $28.80M | $14.80M | $21.40M |
| Operating Expenses | $37.10M | $29.50M | $36.50M | $25.50M |
| Total Costs & Expenses | $147.20M | $180.10M | $158.00M | $131.20M |
| Interest Income | $5.00M | $5.60M | $1.90M | $1.70M |
| Interest Expense | $12.10M | $11.80M | $9.50M | $10.00M |
| Depreciation & Amortization | $8.47M | $8.47M | $1.90M | $1.70M |
| EBITDA | -$18.00M | $3.30M | -$5.40M | $27.30M |
| EBITDA Ratio | -$0.14 | $0.02 | -$0.04 | $0.17 |
| Operating Income | -$23.00M | $23.40M | -$7.30M | $25.60M |
| Operating Income Ratio | -$0.19 | $0.11 | -$0.05 | $0.16 |
| Other Income/Expenses (Net) | -$7.10M | -$21.40M | -$7.60M | -$8.30M |
| Income Before Tax | -$30.10M | $2.10M | -$14.90M | $17.30M |
| Income Before Tax Ratio | -$0.24 | $0.01 | -$0.10 | $0.11 |
| Income Tax Expense | -$8.70M | $5.60M | -$5.60M | $7.60M |
| Net Income | -$21.40M | -$3.50M | -$9.30M | $9.70M |
| Net Income Ratio | -$0.17 | -$0.02 | -$0.06 | $0.06 |
| EPS | -$0.55 | -$0.09 | -$0.25 | $0.25 |
| Diluted EPS | -$0.55 | -$0.09 | -$0.25 | $0.25 |
| Weighted Avg Shares Outstanding | $38.91M | $35.79M | $39.57M | $39.57M |
| Weighted Avg Shares Outstanding (Diluted) | $38.91M | $38.69M | $39.57M | $39.57M |
The company's financials show resilient growth, with revenue advancing from $156.80M in Q2 2024 to $124.20M in Q1 2025. Gross profit remained healthy with margins at 11% in Q1 2025 compared to 33% in Q2 2024. Operating income hit -$23.00M last quarter, sustaining a consistent -19% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$18.00M. Net income dropped to -$21.40M, while earnings per share reached -$0.55. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan